NeurAxis, Inc. (NRXS)
:NRXS
Want to see NRXS full AI Analyst Report?
NRXS Stock Chart & Stats
$7.22
-$0.04(-1.54%)
At close: 4:00 PM EST
$7.22
-$0.04(-1.54%)
Day’s Range― - ―
52-Week Range$1.94 - $8.40
Previous CloseN/A
Volume9.85K
Average Volume (3M)55.04K
Market Cap
$85.72M
Enterprise Value$81.05M
Total Cash (Recent Filing)$4.97M
Total Debt (Recent Filing)$416.61K
Price to Earnings (P/E)―
Beta0.72
Next Earnings
May 27, 2026EPS Estimate
-0.19Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.18
Shares Outstanding11,505,421
10 Day Avg. Volume34,967
30 Day Avg. Volume55,039
Financial Highlights & Ratios
PEG Ratio0.24
Price to Book (P/B)12.13
Price to Sales (P/S)11.55
P/FCF Ratio-6.38
Enterprise Value/Market Cap0.95
Enterprise Value/Revenue22.71
Enterprise Value/Gross Profit26.96
Enterprise Value/Ebitda-10.57
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.54
Revenue Forecast (FY)$9.55M
Bulls Say, Bears Say
Bulls Say
Sustained Revenue And Unit Growth With High Gross MarginsConsistent top-line momentum and repeated double-digit unit growth across seven quarters indicate durable commercial traction and product-market fit. Combined with very high gross margins (~84–85%), these trends imply scalable unit economics that can support profitable growth as fixed cost absorption improves over the next 2–6 months.
Material Reimbursement And Coverage ProgressSecuring a Category I CPT code plus sizable payer and VA coverage creates structural reimbursement channels that reduce access friction for providers. These coding and policy wins are long-lived enablers for sustained procedure adoption, addressing a core barrier to commercialization and supporting predictable revenue growth over the medium term.
Improved Near-term Liquidity And Manageable LeverageRecent equity proceeds and available ATM capacity materially extend runway versus the quarter-end cash balance, reducing immediate dilution pressure. Combined with very low reported debt, the company retains financial flexibility to fund commercialization and payer engagement initiatives while it works toward self-funded growth.
Bears Say
Persistent Cash Burn And Operating LossesOngoing negative operating and free cash flows demonstrate the business currently cannot self-fund growth. Continued cash burn necessitates further financings or rapid margin and revenue scaling; failure to materially reduce burn would pressure liquidity and force dilution or cutbacks, constraining durable commercialization plans.
Gross Margin Pressure From Product Mix, Discounts, InventoryErosion of high gross margins due to lower‑margin product mix, inventory reserves and increased financial assistance undermines the company’s attractive unit economics. If the mix shift persists, it will slow margin expansion, extend the time to positive operating cash flow, and make the business more dependent on scale to offset lower per-unit profitability.
Concentrated Adoption And Delayed Adult Coverage Requiring RCTAdoption is currently top‑heavy and constrained by institutional processes, limiting near-term utilization upside even with reimbursement in place. Additionally, the need for a large adult RCT to unlock broader adult payer policies delays expansion into the larger adult market, making meaningful scale dependent on clinical trial execution and multi-quarter outcomes.
NeurAxis, Inc. News
NRXS FAQ
What was NeurAxis, Inc.’s price range in the past 12 months?
NeurAxis, Inc. lowest stock price was $1.94 and its highest was $8.40 in the past 12 months.
What is NeurAxis, Inc.’s market cap?
NeurAxis, Inc.’s market cap is $85.72M.
When is NeurAxis, Inc.’s upcoming earnings report date?
NeurAxis, Inc.’s upcoming earnings report date is May 27, 2026 which is in 26 days.
How were NeurAxis, Inc.’s earnings last quarter?
NeurAxis, Inc. released its earnings results on Mar 19, 2026. The company reported -$0.18 earnings per share for the quarter, beating the consensus estimate of -$0.215 by $0.035.
Is NeurAxis, Inc. overvalued?
According to Wall Street analysts NeurAxis, Inc.’s price is currently Overvalued.
Does NeurAxis, Inc. pay dividends?
NeurAxis, Inc. does not currently pay dividends.
What is NeurAxis, Inc.’s EPS estimate?
NeurAxis, Inc.’s EPS estimate is -0.19.
How many shares outstanding does NeurAxis, Inc. have?
NeurAxis, Inc. has 11,505,421 shares outstanding.
What happened to NeurAxis, Inc.’s price movement after its last earnings report?
NeurAxis, Inc. reported an EPS of -$0.18 in its last earnings report, beating expectations of -$0.215. Following the earnings report the stock price went up 2.432%.
Which hedge fund is a major shareholder of NeurAxis, Inc.?
Currently, no hedge funds are holding shares in NRXS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
NeurAxis, Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
― (―)
― (―)
Insider Transactions
Bought Shares
Worth $32.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 3.5%
Last 30 Days ▲ 39.5%
Last 30 Days ▲ 39.5%
Technicals
SMA
Positive
20 days / 200 days
Momentum
17.07%
12-Months-Change
Fundamentals
Return on Equity
-306.02%
Trailing 12-Months
Asset Growth
34.61%
Trailing 12-Months
Company Description
NeurAxis, Inc.
NeurAxis, Inc. operates as a neuromodulation therapy device company in the United States. It offers IB-Stim, a percutaneous electrical nerve field stimulation system intended to be used in patients 11-18 years of age with functional abdominal pain associated with irritable bowel syndrome healthcare companies primarily hospitals and clinics. The company was formerly known as Innovative Health Solutions, Inc. and changed its name to NeurAxis, Inc. in March 2022. The company was founded in 2011 and is headquartered in Carmel, Indiana.
NRXS Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call communicated a clear progression from regulatory and coverage milestones toward commercialization: a Category I CPT code, a ~45M member major payer policy, an FSS contract with the VA, sustained unit and revenue growth, and strengthened liquidity. Management also outlined concrete commercial hiring and payer engagement plans and multiple ongoing clinical trials to expand adult and other-indication coverage. Offsetting these positives are margin compression driven by product mix and inventory adjustments, higher operating expenses that increased quarterly losses, uneven hospital adoption due to operational/administrative barriers, and the need for additional payer policies (and an adult RCT) to unlock broader adoption. Overall, the upside from reimbursement wins, regulatory progress, accelerating submissions and funded runway meaningfully outweighs the execution and margin challenges in the near term.View all NRXS earnings summariesNRXS Stock 12 Month Forecast
Average Price Target
―Technical Analysis
Ownership Overview
11.81% Insiders
1.54% Mutual Funds
6.59% Other Institutional Investors
78.10% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---